TISIDB

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell projection, dendrite Perikaryon
Domain	PF16474 Kinase non-catalytic C-lobe domain PF00617 RasGEF domain PF00618 RasGEF N-terminal motif
Function	RAS-Guanine nucleotide exchange factor (GEF) that controls the negative regulation of neuronal dendrite growth by mediating a signaling pathway linking RAS and MAP2 (By similarity). May be involved in cellular senescence (PubMed:24788352).

> Gene Ontology [ TOP ]
Biological Process	GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0016358 dendrite development GO:0021533 cell differentiation in hindbrain GO:0021549 cerebellum development GO:0021575 hindbrain morphogenesis GO:0021587 cerebellum morphogenesis GO:0021681 cerebellar granular layer development GO:0021683 cerebellar granular layer morphogenesis GO:0021684 cerebellar granular layer formation GO:0021695 cerebellar cortex development GO:0021696 cerebellar cortex morphogenesis GO:0021697 cerebellar cortex formation GO:0021707 cerebellar granule cell differentiation GO:0021953 central nervous system neuron differentiation GO:0022037 metencephalon development GO:0022604 regulation of cell morphogenesis GO:0030902 hindbrain development GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048813 dendrite morphogenesis GO:0048814 regulation of dendrite morphogenesis GO:0050773 regulation of dendrite development
Molecular Function	GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity
Cellular Component	GO:0030425 dendrite GO:0032045 guanyl-nucleotide exchange factor complex GO:0043025 neuronal cell body GO:0044297 cell body

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KNDC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KNDC1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KNDC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.167	0.415
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.126	0.803
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.383	0.371
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.277	0.731
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.679	0.228
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.492	0.359
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.387	0.645
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.577	0.697
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.412	0.772
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.873	0.202
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.998	0.268
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.922	0.00207

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KNDC1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	0	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	0	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	5.9	8.4	0.613
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	18.8	-7.7	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KNDC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KNDC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KNDC1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KNDC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KNDC1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KNDC1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KNDC1
Name	kinase non-catalytic C-lobe domain (KIND) containing 1
Aliases	KIAA1768; bB439H18.3; FLJ25027; RASGEF2; C10orf23; RasGEF domain family, member 2; KIND domain-containing pr ......
Chromosomal Location	10q26.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KNDC1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KNDC1